Jan Skvarka

Filings by Jan Skvarka span 2 companies, the busiest being Trillium Therapeutics Inc. and Zentalis Pharmaceuticals, Inc. The record holds 15 filings, for trades running from 13 January 2021 to 17 June 2025.

The open-market side counts 1 purchase for €99k alongside 5 sales for €1.4M. Netting one side against the other leaves €1.3M of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 4 share grants and 5 option exercises. 2025 to date brings 1 purchase and no sales.

The latest filing, published on 18 June 2025, reports a share grant in Zentalis Pharmaceuticals, Inc. The most recent open-market purchase was published on 4 February 2025, 627 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.